Laekna, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wuxi Biologics (Cayman), Inc.

3SBio, Inc.

Alphamab Oncology

CSPC Pharmaceutical Group Ltd.

Sirnaomics Ltd.

Ascentage Pharma Group International Co., Ltd.

AIM Vaccine Co., Ltd.

Zai Lab Ltd.

Beijing Lüzhu Biotechnology Co., Ltd.

Laekna, Inc.

Genscript Biotech Corp.

Why is Laekna, Inc. ?

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 12.73% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Flat results in Jun 25

INTEREST(Q) Highest at HKD 2.18 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 20.80%, its profits have risen by 12%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Laekna, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Laekna, Inc.

20.8%

1.48

96.64%

Hang Seng Hong Kong

27.36%

1.06

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

12.73%

EBIT to Interest (avg)

-132.76

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

8.54

EV to EBIT

-19.06

EV to EBITDA

-19.40

EV to Capital Employed

67.18

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-352.57%

ROE (Latest)

-35.30%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at HKD -139.25 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-4What is not working for the Company

INTEREST(Q)

Highest at HKD 2.18 MM

Here's what is working for Laekna, Inc.

Net Profit

Higher at HKD -139.25 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (HKD MM)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Laekna, Inc.

Interest

Highest at HKD 2.18 MM

in the last five periods and Increased by 18.29% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)